Helius Medical Technologies (HSDT) Downgraded by ValuEngine to “Sell”
Helius Medical Technologies (OTCMKTS:HSDT) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday.
Helius Medical Technologies (OTCMKTS HSDT) traded down $0.05 during trading hours on Friday, reaching $2.23. The company’s stock had a trading volume of 16,145 shares, compared to its average volume of 90,443. Helius Medical Technologies has a 12 month low of $1.29 and a 12 month high of $4.14.
In other news, Director Dane Andreeff acquired 167,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were purchased at an average price of $2.58 per share, for a total transaction of $430,860.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Blane Walter acquired 40,000 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was purchased at an average price of $2.46 per share, for a total transaction of $98,400.00. The disclosure for this purchase can be found here. 23.00% of the stock is currently owned by insiders.
Helius Medical Technologies Company Profile
Helius Medical Technologies, Inc is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Helius Medical Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.